1.57
+0.09(+6.08%)
Currency In USD
Address
The MediaWorks
London, W12 7FP
United Kingdom of Great Britain and Northern Ireland
Phone
44 20 3829 6230
Website
Sector
Healthcare
Industry
Biotechnology
Employees
647
First IPO Date
June 22, 2018
| Name | Title | Pay | Year Born |
| Dr. Christian Martin Itin Ph.D. | Chief Executive Officer & Director | 2.52M | 1964 |
| Mr. Alex Driggs | Senior Vice President of Legal Affairs & General Counsel and Secretary | 0 | 1976 |
| Dr. Christopher Williams | Chief Business Officer | 0 | 1980 |
| Mr. Patrick McIlvenny | Senior Vice President of Finance & Chief Accounting Officer | 0 | 1979 |
| Ms. Miranda Neville | Chief Technology Officer | 0 | N/A |
| Dr. Martin Pule M.D., MBBS | Founder, Senior Vice President & Chief Scientific Officer | 0 | 1972 |
| Dr. Matthias Will M.D. | Senior Vice President & Chief Development Officer | 0 | 1973 |
| Ms. Olivia Manser | Director of Investor Relations | 0 | N/A |
| Mr. Christopher Vann | Senior Vice President & Chief Operating Officer | 0 | 1965 |
| Mr. Robert F. Dolski | Senior Vice President & Chief Financial Officer | 0 | 1970 |
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.